English  |  正體中文  |  简体中文  |  2856655  
???header.visitor??? :  53554154    ???header.onlineuser??? :  1187
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"ou d l"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 6-15 of 103  (11 Page(s) Totally)
1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-08-19T00:20:43Z Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression Ou D.-L.; Cheng A.-L.; Shao Y.-Y.; Feng Z.-R.; Lin L.-I.; Cheng Y.-C.; CHIUN HSU
臺大學術典藏 2022-08-19T00:20:40Z Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy CHIUN HSU; Ou D.-L.; Cheng A.-L.; Chen C.-W.; Tan C.-T.; Lin Y.-Y.
臺大學術典藏 2022-08-19T00:20:40Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy CHIUN HSU; Wang M.-J.; Cheng A.-L.; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.
臺大學術典藏 2022-08-19T00:20:38Z Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma Hsu P.-N.; Cheng A.-L.; CHIUN HSU; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu C.-L.; Lin Y.-Y.; Ou D.-L.
臺大學術典藏 2022-08-19T00:20:30Z Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages Ou D.-L.; Chen C.-W.; Hsu C.-L.; Chung C.-H.; Feng Z.-R.; Lee B.-S.; Cheng A.-L.; Yang M.-H.; CHIUN HSU
臺大學術典藏 2022-08-19T00:20:25Z Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer Jian C.-Z.; Ou P.-Y.; Ou D.-L.; Hsieh C.-H.; Lin L.-I.; Low G.-S.; CHIUN HSU
臺大學術典藏 2022-08-19T00:20:23Z Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma Shao Y.-Y.; Lin L.-I.; Ling A.; CHIUN HSU; Chen P.-S.; Lee B.-S.; Cheng A.-L.; Ou D.-L.
臺大學術典藏 2022-06-10T06:11:04Z Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; ZHONG-ZHE LIN; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:10:59Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏 2022-03-29T07:00:05Z Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma Shen Y.-C.; Ou D.-L.; Hsu C.; Lin K.-L.; Chang C.-Y.; CHING-YU LIN; Liu S.-H.; Cheng A.-L.

Showing items 6-15 of 103  (11 Page(s) Totally)
1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page